Clinical Efficacy among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease: Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 Studies
Jorge F Maspero,Claus Bachert,Fernando J Martinez,Nicola A Hanania,Benjamin Ortiz,Naimish Patel,Leda P Mannent,Amy Praestgaard,Nami Pandit-Abid,Shahid Siddiqui,Megan Hardin
DOI: https://doi.org/10.2147/JAA.S357393
2023-04-01
Journal of Asthma and Allergy
Abstract:Jorge F Maspero, 1 Claus Bachert, 2, 3 Fernando J Martinez, 4 Nicola A Hanania, 5 Benjamin Ortiz, 6 Naimish Patel, 7 Leda P Mannent, 8 Amy Praestgaard, 7 Nami Pandit-Abid, 9 Shahid Siddiqui, 6 Megan Hardin 7 1 Allergy and Respiratory Research Unit, Fundación CIDEA, Buenos Aires, Argentina; 2 Upper Airway Research Laboratory, Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium; 3 Division of ENT Diseases, CLINTEC, Karolinska Institutet, Stockholm, Sweden; 4 Division of Pulmonary and Critical Care, Weill Cornell Medical College, New York, NY, USA; 5 Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA; 6 Immunology and Allergy Medical Affairs, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 7 Immunology and Inflammation, Sanofi, Cambridge, MA, USA; 8 Global Clinical Development, Sanofi, Chilly-Mazarin, France; 9 Immunology and Inflammation, Sanofi, Bridgewater, NJ, USA Correspondence: Jorge F Maspero, Allergy and Respiratory Research Unit, Fundación CIDEA, Paraguay 2035, Buenos Aires, C1121ABE, Argentina, Tel +54 91141837294, Email Purpose: To provide a descriptive summary of clinical efficacy and health-related quality of life (HRQoL) measures in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and clinical features of obstructive lung disease in the Phase III dupilumab studies SINUS-24 and SINUS-52 (NCT02912468, NCT02898454). Patients and Methods: Patients met a "broad" definition of having clinical features of obstructive lung disease with any of 3 criteria: (i) pre-bronchodilator forced expiratory volume in 1 second (FEV 1 )/forced vital capacity (FVC) 10 pack-years' smoking history. A "narrow" definition including criteria (i) or (ii) was also analyzed. CRSwNP and HRQoL measures were evaluated in all patients and lung function (FEV 1 ; FEV 1 /FVC ratio) was captured and analyzed only in those patients who had a self-reported history of asthma. Results: Across both studies, 131 patients met the "broad" definition, of whom 90 also had asthma, and 115 patients met the "narrow" definition, of whom 74 had asthma. CRSwNP outcomes and HRQoL were improved with dupilumab vs placebo in both the broad and narrow subgroups. Among the 90 patients who met the broad definition and had asthma, dupilumab improved pre-bronchodilator FEV 1 and FEV 1 /FVC ratio at Week 16 (least squares mean differences vs placebo: 0.38 L [95% confidence interval: 0.17, 0.59; p = 0.0004] and 4.8% [1.7%, 7.9%; p = 0.0024], respectively) sustained through Week 24. Similar results were seen in the "narrow" subgroup with asthma. Conclusion: In a population of patients with CRSwNP and clinical features of obstructive lung disease, dupilumab improved CRSwNP and HRQoL outcomes, and, among those with a history of asthma, also improved lung function. These results support further analyses of dupilumab in patients with evidence of type 2 inflammation and obstructive lung disease such as COPD. Keywords: obstructive lung disease, chronic obstructive pulmonary disease, dupilumab, type 2 inflammation, interleukin-4, interleukin-13 Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disease of the nasal cavity and paranasal sinuses characterized by chronic symptoms such as nasal congestion, rhinorrhea, loss of smell, facial pain and headache, and the presence of nasal polyps (NP) and sinus inflammation. 1 Inflammation in CRSwNP is commonly type 2 and involves interleukin (IL)-4 and IL-13, which are key and central drivers of type 2 inflammation in multiple diseases. 1–3 Dupilumab is a fully human VelocImmune ® -derived monoclonal antibody that binds specifically to IL-4Rα, the shared receptor component for IL-4 and IL-13, thereby inhibiting the proinflammatory actions of these cytokines. 4,5 Dupilumab demonstrated an acceptable tolerability profile in Phase 1 studies in healthy volunteers and demonstrated efficacy and acceptable tolerability in Phase 2 and Phase 3 studies in a range of conditions, including asthma, atopic dermatitis, and CRSwNP. 6–14 Dupilumab improved lung function and asthma control in adults and adolescents with moderate-to-severe asthma and evidence of type 2 inflammation. 11 Dupilumab is approved for selected patients with diseases driven by type 2 inflammation, specifically asthma, CRSwNP, and a -Abstract Truncated-
immunology,allergy,respiratory system